Association of patient, physician and visit characteristics with inappropriate antibiotic prescribing in Japanese primary care: a cross-sectional study
- PMID: 40842720
- PMCID: PMC12366620
- DOI: 10.1136/bmjph-2024-002364
Association of patient, physician and visit characteristics with inappropriate antibiotic prescribing in Japanese primary care: a cross-sectional study
Abstract
Objective: To assess the prevalence and associated factors of inappropriate antibiotic prescribing in Japanese primary care.
Methods: This cross-sectional study analysed all antibiotic prescriptions written between 1 October 2022 and 30 September 2023, using an electronic health record database of primary care clinics across Japan. Using a previously developed classification algorithm, we determined whether diagnosis codes occurring on or during the 3 days before the antibiotic prescribing date 'always', 'sometimes' or 'never' justified antibiotic use. We classified antibiotic prescriptions into one of four mutually exclusive categories: 'appropriate' (associated with ≥1 'always' code), 'potentially appropriate' (associated with ≥1 'sometimes' code but no 'always' codes), 'inappropriate' (associated only with 'never' codes) and 'not associated with a recent diagnosis'. A linear probability model examined patient, physician and visit characteristics associated with inappropriate antibiotic prescribing among solo practice clinics.
Results: Analyses included 2 058 021 outpatient antibiotic prescriptions to 1 267 708 patients at 2809 clinics. Among these prescriptions, 176 181 (8.6%) were appropriate, 1 238 549 (60.2%) were potentially appropriate, 348 949 (17.0%) were inappropriate and 294 342 (14.3%) were not associated with a recent diagnosis. Among solo practice clinics, inappropriate prescribing was more likely to patients aged <18 versus ≥65 years (+2.6%; 95% CI +0.3% to +4.9%) or with Charlson Comorbidity Index score ≥2 vs 0 (+2.0%; 95% CI +0.6% to +3.4%), for physicians aged ≥65 versus <45 years (+7.3%; 95% CI +3.6% to +11.0%), for physicians in the highest tertile of antibiotic prescribing volume (+4.9%; 95% CI +3.0% to +6.8%), during telehealth visits (+3.9% vs office visits; 95% CI +0.02% to +7.7%) and during regular hours care versus after hours care (+2.1%; 95% CI +0.7% to +3.5%). These findings were qualitatively unchanged when including both solo and group practice clinics.
Conclusions: Targeting younger patients, patients with comorbidities, older physicians, physicians with high antibiotic prescribing, telehealth visits and regular hours care may further increase stewardship effectiveness.
Keywords: Communicable Disease Control; Epidemiological Monitoring; Public Health.
Copyright © Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. Published by BMJ Group.
Conflict of interest statement
AM reported receiving consulting fees from M3, Inc., which provides the JAMDAS database used in this article, outside the submitted work. JBL-L reported receiving a Resident Research Grant from the American Academy of Pediatrics, a Physician Investigator Award from Blue Cross Blue Shield Foundation of Michigan (award #2022040061), and a Research Grant from the National Med-Peds Residents’ Association outside the submitted work. KK reported receiving personal fees from M3, Inc as an employee outside the submitted work. DS reported receiving personal fees from M3, Inc during the conduct of the study. JAL is supported by grants from the Agency for Healthcare Research and Quality (R01HS029328), The National Institute on Aging (R21AG081895, R24AG064025, U19AG065188, R01AG070054, P30AG024968-20S1, R01AG074245, R01AG069762, P30AG059988), the National Heart, Lung, and Blood Institute (R01HL167023) and the National Institute of Neurological Disorders and Stroke (U01NS105562). K-PC reported consulting fees from the U.S. Department of Justice and the Benter Foundation outside the submitted work. YT receives funding from the National Institute of Health (award number: R01AG068633, R01AG082991, and R01MD013913) and GRoW @ Annenberg for other work not related to this study, and serves on the board of directors of M3, Inc.
Figures

References
-
- World Health Organization Antimicrobial Resistance. 2023. [31-May-2025]. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance Available. Accessed.
-
- World Health Organization Global action plan on antimicrobial resistance. 2016. [31-May-2025]. https://www.who.int/publications-detail-redirect/9789241509763 Available. Accessed.
Grants and funding
LinkOut - more resources
Full Text Sources